GDC-0339 - ≥99% , CAS No.1428569-85-0

CAS: 1428569-85-0 Cat. No.: G646647 Summenformel: C20H22F3N7OS Molekulargewicht: 465.50 PubChem CID: 73603034
Zu bestellen verfügbar
QUALITÄT & REINHEIT ≥99%
Synonyms
5-Amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide|5-amino-N-{5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methyl-1H-pyrazol-4-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide|5-amino-N-{5-[(4r,5r)-4-amino-5-fluoro-1-azepanyl]-1-methyl-1h-pyrazol-4-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide|GDC0339|GDC-0339|KUV|5-amino-N-[5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methylpyrazol-4-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Größe
Deutschland (EU)
USA*
Preis
Menge
1mg
G646647-1mg
Auf Bestellung · 8–12 Wochen
330,52€
5mg
G646647-5mg
Auf Bestellung · 8–12 Wochen
868,52€
10mg
G646647-10mg
Auf Bestellung · 8–12 Wochen
1.389,16€
50mg
G646647-50mg
Auf Bestellung · 8–12 Wochen
4.513,02€
100mg
G646647-100mg
Auf Bestellung · 8–12 Wochen
7.810,43€
Enter a quantity for the sizes you want to add.

Übersicht

GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with K i s of 0.03 nM, 0.1 nM and 0.02 nM for Pim1 , Pim2 and Pim3 , respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma

In Vitro

GDC-0339 is cytostatic, with an IC 50 of 0.1 μM for MM.1S cells. GDC-0339 treatment reveals a constellation of Pim downstream signaling events consistent with inhibition of Pim kinases. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MM.1S cells Concentration: Incubation Time: 3 days Result: Inhibited cell viability. Western Blot AnalysisCell Line: MM.1S cells Concentration: 0.01 μM, 0.03 μM, 0.09 μM,0.27 μM, 0.83 μM, 2.5 μM Incubation Time: 4 hours Result: Induced a constellation of Pim downstream signaling events consistent with inhibition of Pim kinases.

In Vivo

GDC-0339 (1-300 mg/kg; p.o; daily; for 21 days) is efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models. GDC-0339 has a half-life of t1/2=0.9 h. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female C.B-17 SCID mice, RPMI8226 human multiple myeloma xenograft mouse modelDosage: 1mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg, 200 mg/kg, 300 mg/kg Administration: Oral administration; once daily; for 21 days Result: Showed dose-dependent tumor growth inhibition.

Form:Solid

IC50& Target:Ki: 0.03 nM (Pim1), 0.1 nM (Pim2), 0.02 nM (Pim3)

Spezifikationen

Synonyme
5-Amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide | 5-amino-N-{5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methyl-1H-pyrazol-4-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide | 5-amino-N-{5-[(4r,5r)-4-amino-5-fluoro-1-azepanyl]-1-methyl-1h-pyrazol-4-yl}-2-(2,6-dif Show more
Spezifikationen & Reinheit
≥99%
Biochemische und physiologische Mechanismen
GDC-0339 is a potent, orally bioavailable and well tolerated pan-Pim kinase inhibitor, with K i s of 0.03 nM, 0.1 nM and 0.02 nM for Pim1 , Pim2 and Pim3 , respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma.
Storage
Store at -20°C
Verschickt in
Ice chest + Ice pads
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Aktionsart
INHIBITOR
Reinheit
≥99%
Namen und Kennungen
SMILES
CN1C(=C(C=N1)NC(=O)C2=C(SC(=N2)C3=C(C=CC=C3F)F)N)N4CCC(C(CC4)F)N
IUPAC Name
5-amino-N-[5-[(4R,5R)-4-amino-5-fluoroazepan-1-yl]-1-methylpyrazol-4-yl]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide
InChIKey
NHXVGMQFCYBLTL-ZWNOBZJWSA-N
InChI
1S/C20H22F3N7OS/c1-29-20(30-7-5-10(21)13(24)6-8-30)14(9-26-29)27-18(31)16-17(25)32-19(28-16)15-11(22)3-2-4-12(15)23/h2-4,9-10,13H,5-8,24-25H2,1H3,(H,27,31)/t10-,13-/m1/s1
Isomere SMILES
CN1C(=C(C=N1)NC(=O)C2=C(SC(=N2)C3=C(C=CC=C3F)F)N)N4CC[C@H]([C@@H](CC4)F)N
Alternative CAS-Nummer
1428569-85-0
PubChem CID
73603034
Molekulargewicht
465.50

Erweiterte Daten

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassOrganoheterocyclic compounds
KlasseAzoles
SubclassThiazoles
Intermediate Tree Nodes Thiazolecarboxylic acids and derivatives
Direct ParentThiazolecarboxamides
Alternative Parents 2,4,5-trisubstituted thiazoles  2-heteroaryl carboxamides  Dialkylarylamines  Azepanes  Fluorobenzenes  Aminothiazoles  Aryl fluorides  Heteroaromatic compounds  Pyrazoles  Vinylogous amides  Secondary carboxylic acid amides  Amino acids and derivatives  Azacyclic compounds  Hydrocarbon derivatives  Organofluorides  Organooxygen compounds  Alkyl fluorides  Monoalkylamines  Organic oxides  
Molecular FrameworkAromatic heteromonocyclic compounds
Substituents 2-heteroaryl carboxamide - 2,4,5-trisubstituted 1,3-thiazole - Dialkylarylamine - Thiazolecarboxamide - Azepane - Fluorobenzene - Halobenzene - 1,3-thiazolamine - Aryl fluoride - Aryl halide - Monocyclic benzene moiety - Benzenoid - Heteroaromatic compound - Vinylogous amide - Pyrazole - Amino acid or derivatives - Carboxamide group - Secondary carboxylic acid amide - Azacycle - Carboxylic acid derivative - Alkyl halide - Alkyl fluoride - Primary aliphatic amine - Organohalogen compound - Organofluoride - Organic nitrogen compound - Hydrocarbon derivative - Organic oxide - Organic oxygen compound - Organonitrogen compound - Amine - Organooxygen compound - Primary amine - Aromatic heteromonocyclic compound
BeschreibungThis compound belongs to the class of organic compounds known as thiazolecarboxamides. These are heterocyclic compounds containing a thiazole ring which bears a carboxylic acid amide group.
External Descriptors Not available
3D-Struktur
Interaktives chemisches Strukturmodell





Zugehörige Ziele (menschlich)
PIM1 Tchem Serine/threonine-protein kinase pim-1 (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PIM2 Tchem Serine/threonine-protein kinase pim-2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PIM3 Tchem Serine/threonine-protein kinase pim-3 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ABL1 Tclin Tyrosine-protein kinase ABL (18331 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GSK3B Tclin Glycogen synthase kinase-3 beta (11785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CSNK1D Tchem Casein kinase I delta (4546 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIM1 Tchem Serine/threonine-protein kinase PIM1 (9629 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDK2 Tchem Cyclin-dependent kinase 2 (9050 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKA Tchem Serine/threonine-protein kinase Aurora-A (10240 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIM2 Tchem Serine/threonine-protein kinase PIM2 (5873 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RPMI-8226 (44974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
U2OS (164939 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIM3 Tchem Serine/threonine-protein kinase PIM3 (4133 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAP4K4 Tchem Mitogen-activated protein kinase kinase kinase kinase 4 (2886 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BRD4 Tchem Bromodomain-containing protein 4 (13122 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TRIM24 Tchem Transcription intermediary factor 1-alpha (2087 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BRPF1 Tchem Peregrin (2217 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIM1 Tchem Serine/threonine-protein kinase PIM (115 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK-293T (167025 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Zugehörige Ziele (nicht menschlich)
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Fgfr3 Fibroblast growth factor receptor 3 (21 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Drd5 Dopamine receptor (1304 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Wirkungsmechanismen
Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemische und physikalische Eigenschaften
LöslichkeitDMSO : ≥ 52 mg/mL (111.71 mM)
Molekulargewicht465.500 g/mol
XLogP33.000
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count4
Exact Mass465.156 Da
Monoisotopic Mass465.156 Da
Topological Polar Surface Area143.000 Ų
Heavy Atom Count32
Formal Charge0
Complexity657.000
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Lösungsrechner
Bewertungen

Kundenbewertungen

Application Protocols
  • Item-specific validated applications and conditions

    • Not specified for this item; no tested applications, assay formats, or recommended dilutions are provided in the Product Data.
  • General starting points for small-molecule screening (not item-specific)

    • Biochemical enzyme assays: prepare 10 mM DMSO stocks; test in 10-point half-log dilutions (e.g., 0.03–100 µM final), maintaining constant DMSO across wells.
    • Cell-based assays: typical top concentrations of 10–30 µM with serial dilutions, observing cell-line specific DMSO tolerances (commonly ≤0.1–0.5% v/v).
    • Counterscreens: include orthogonal readouts to exclude fluorescence/absorbance artifacts and aggregate-based inhibition (e.g., add 0.01–0.05% nonionic detergent where appropriate).
    • Data quality: include intra-plate controls and calculate Z’ factor to assess assay robustness.

These are general templates. Optimize parameters upon obtaining compound-specific data from the CoA or preliminary experiments.

Biological Roles
  • Item-specific biological function/target

    • Not specified for this item; no mechanism of action, target class, or pathway information is provided in the current Product Data for GDC-0339. For any target specificity claims, consult the CoA or a product technical sheet.
  • General notes for small-molecule research tools (not item-specific)

    • Small molecules in discovery libraries are often used to modulate enzymes, receptors, transporters, or protein–protein interactions in vitro. They serve for target validation, pathway mapping, and SAR development.
    • Prior to biological testing, confirm compound identity and purity, and determine basic physicochemical properties (solubility in assay media, stability, and permeability if relevant).
    • Establish assay-relevant concentration ranges with attention to DMSO tolerance and potential off-target effects at higher micromolar exposures.
    • Evaluate interference risks: fluorescence/absorbance overlap in reporter assays, redox cycling, aggregation (use detergent controls), or metal chelation artifacts.
  • Documentation and controls

    • Include appropriate negative (vehicle) and positive controls in each assay plate.
    • If no validated biological role is known, report findings as preliminary and contingent on compound identity/quality verification.

Note: This product is for research use only; no clinical or diagnostic claims are made or implied.

Buffer Applications

This section is generally not directly applicable to a discrete small-molecule screening compound lacking acid/base specification or buffering capacity.

  • Item-specific buffer usage

    • Not specified for this item; refer to CoA/Spec Sheet.
  • General guidance for preparing assay solutions (not item-specific)

    • Prepare primary stocks in DMSO, then dilute into biologically compatible buffers (e.g., PBS, HEPES, or assay-specific buffers) ensuring final DMSO content is within tolerated limits (often ≤0.1–1% v/v).
    • If the compound is known to be acid/base ionizable, select buffer pH to maintain the desired ionization state for permeability or target engagement. Perform small-scale pH-solubility tests if needed.
    • Filter sterilize (0.22 µm) only when chemically compatible; many hydrophobic molecules exhibit filter binding—verify recovery.

Since no pKa or buffer-related data are provided for this item, rely on general assay buffer best practices and confirm compatibility empirically.

Green Alternatives

This section discusses greener options for solvents and processes used with small-molecule screening compounds in general; item-specific green metrics for GDC-0339 are not available.

  • Solvent considerations (general)

    • Prefer bio-based or lower-toxicity solvents where feasible: 2-MeTHF over THF for extractions; CPME or EtOAc over DCM/CHCl3; MeOH/EtOH over acetonitrile when chromatographically acceptable.
    • Use water-rich mobile phases and volatile buffers (formate/acetate) for LC methods, minimizing acetonitrile consumption via shorter columns and gradient optimization.
  • Process and handling

    • Minimize DMSO usage by preparing the highest practical stock concentration that remains stable and filterable, thereby reducing total solvent volume in assays.
    • Implement microplate-based assays and acoustic dispensing to reduce plastic and solvent waste.
  • Small comparison (general; not item-specific)

    • THF vs 2-MeTHF: similar polarity and ether functionality; 2-MeTHF is less prone to peroxide formation and is partly bio-derived, but has a distinct odor and slightly different miscibility profile.
    • DCM vs EtOAc/CPME: greener alternatives reduce halogenated waste, though separation efficiency may differ; method re-optimization may be required.
  • Waste management

    • Segregate halogenated from non-halogenated waste; use solvent recycling where available. Document waste minimization steps in ELNs and internal reports.
Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation-specific information is provided for this item.

  • Item-specific statements

    • Pharmaceutical/formulation use: Not specified for this item; refer to CoA/Spec Sheet.
    • Research Use Only: This material is supplied strictly for research and laboratory use, not for human or veterinary applications, diagnostic procedures, or as an active pharmaceutical ingredient.
  • General considerations for pre-formulation research (not item-specific)

    • If pursuing preclinical enabling studies, determine solid form (salt screening, polymorphs), hygroscopicity, pKa, logD, and intrinsic solubility. Evaluate stability across pH 1–9 and under oxidative/light stress.
    • Early developability screens (solubility enhancement via co-solvents, complexation, amorphous dispersions, or nanosuspensions) are common, but should only proceed once identity and purity are verified.
    • For in vivo exploratory research, ensure appropriate ethical and regulatory approvals and obtain grade suitable for such studies; this listing does not provide that level of qualification.

No medical or clinical claims are made or implied for this product.

Physical Properties

Item-specific properties

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point, boiling point, density, refractive index, pKa, logP/logD, UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

Storage and shipping (from Product Data)

  • Storage: Store at -20°C
  • Shipping: Ice chest + Ice pads

General/literature guidance for small-molecule screening solids (not item-specific)

  • Many discovery compounds are crystalline or amorphous solids with limited aqueous solubility. Initial dissolution is commonly performed in anhydrous DMSO (analytical grade) to prepare a 10–50 mM primary stock, then diluted into aqueous assay buffers (final DMSO ≤0.1–1% v/v depending on biology).
  • If the compound is provided as a salt (e.g., HCl, mesylate), solubility in water or aqueous buffer may be improved relative to the free base/acid; verify form on the CoA.
  • Where pKa values are unknown, pH-shift solubility screening (acidic pH ~2, neutral pH 7.4, basic pH ~9–10) can quickly reveal ionization-assisted dissolution behavior.
  • For optical assays, determine the compound’s UV–vis absorbance profile and potential inner-filter effects prior to high-concentration screening. Acquire spectra of both compound and assay dyes to assess overlap.
  • Hygroscopicity and polymorphism can influence handling and reproducibility; minimize air exposure and record any observed changes in appearance upon opening.
Quality and Grades
  • Item-specific (from Product Data)

    • Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
  • What to expect in CoA/Spec Sheet for small-molecule library members (general guidance)

    • Identity confirmation: typically by 1H NMR and/or LC–MS, sometimes HRMS. Batch-specific HPLC purity (% area) and retention time are commonly included.
    • Form and counterion: free base/acid vs salt form, solvate/hydrate content (if any). This impacts mass calculations for solution prep.
    • Residual solvents and water (KF) may be reported; if not, request upon need for sensitive assays.
    • Assay-relevant controls: information on stereochemistry (enantiomeric or diastereomeric purity) if chiral.
  • Interpreting common grades (general definitions; not item-specific)

    • Screening/Discovery grade: suitable for in vitro assays and method development; not intended for clinical or GMP use.
    • HPLC/LC–MS suitability: indicates low non-volatile residue and acceptable UV background for chromatographic analysis.
  • Practical tips

    • Verify the reported purity and analytical traces match your application needs (e.g., biochemical IC50 screening may tolerate ≥95% HPLC area purity; structural biology or tox assays may require ≥98%).
    • If stabilizers or special handling (inert atmosphere/desiccation) are needed, they will appear on the CoA; none are specified for this item in the current listing.
Reaction and Applications
  • Item-specific applications

    • Manufacturer Applications: Not provided in Product Data.
    • Without structure or functional group information, specific synthetic or mechanistic applications of GDC-0339 cannot be detailed for this item. Refer to the CoA or technical note if available.
  • General research context for small-molecule library members (not item-specific)

    • Such compounds are commonly used in target validation, pathway probing, and structure–activity relationship (SAR) studies in biochemical or cell-based assays.
    • Typical workflows include concentration–response profiling, orthogonal assay confirmation, basic DMPK (solubility, stability, permeability), and selectivity panels.
    • If a reactive handle is present (e.g., amine, carboxyl, halide), analog derivatization for probe development or bioconjugation may be pursued; confirm presence/absence via structure.
  • Practical assay tips

    • Prepare fresh DMSO stocks or store aliquots at -20°C to avoid multiple freeze–thaw cycles. Thaw on ice and vortex/sonicate as needed.
    • Include vehicle controls (matching DMSO %) and, where applicable, positive reference controls for the biological pathway under study.
    • Confirm stability in assay media (e.g., monitor by LC–MS over assay timeframe) to rule out false negatives due to rapid degradation or adsorption.
  • Documentation

    • Capture lot number, exact concentration by weight and corrected for salt/solvate, and any observed precipitation during dilution.
Reaction Conditions

Item-specific reaction conditions cannot be provided due to absent structural information.

  • Not specified for this item; refer to CoA/Spec Sheet for any available test reactions or stability notes.

General guidance for handling unknown or unspecified small molecules in lab operations (not item-specific)

  • Solution preparation: dissolve in dry DMSO (10–50 mM), vortex and, if needed, sonicate briefly. Avoid prolonged heating unless stability is confirmed.
  • Stability checks: assess by LC–MS in your intended solvent system over the experiment time course (e.g., 0, 2, 24 hours at room temperature and 37°C as applicable).
  • Photostability: assume potential light sensitivity; use amber vials and limit exposure until UV–vis profile is known.
  • Adsorption: evaluate nonspecific binding to plastics by comparing concentrations in glass vs polypropylene tubes for low-µM solutions.
  • Filtration: confirm recovery across membrane materials (PTFE, PES, nylon) before routine sterile filtration of working solutions.

These are general best practices and not product specifications. Tailor conditions once the structure and properties are confirmed.

Safety and Handling

Safety information provided for this item is limited.

  • Item-specific (from Product Data)

    • GHS classification: Not specified for this item; refer to SDS.
    • Signal word: Not specified for this item; refer to SDS.
    • H-statements/Pictograms: Not specified for this item; refer to SDS.
    • Storage: Store at -20°C. Shipments are supplied in an ice chest with ice pads.
    • Research Use Note: For research use only.
  • Practical laboratory precautions (general guidance for small molecules; defer to SDS for this product)

    • Handle in a chemical fume hood; avoid inhalation of dust or aerosols. Prevent skin and eye contact.
    • Recommended PPE: lab coat, safety glasses, and suitable chemical-resistant gloves (e.g., nitrile). For weighing fine powders, consider a balance enclosure or local exhaust.
    • Avoid incompatible reagents until identity and functional groups are confirmed (e.g., strong oxidizers/reductants, strong acids/bases).
    • In case of skin/eye contact: rinse with water for at least 15 minutes; remove contaminated clothing. Seek medical advice as per institutional protocols.
    • Spill response: avoid dust generation; collect mechanically or with damp disposable wipes; dispose according to local regulations.
    • Thermal stability: maintain at recommended storage (-20°C). Do not expose to unnecessary freeze-thaw or elevated temperatures.

Always consult the product-specific SDS and CoA for authoritative hazard, toxicological, and disposal information before use.

Solvent Selection
  • Item-specific solvent data

    • Solubility, partitioning, and preferred solvents: Not specified for this item; refer to CoA/Spec Sheet.
  • General strategy for dissolving small-molecule screening compounds (not item-specific)

    • Start with anhydrous DMSO for primary stock solutions (e.g., 10–50 mM). If insoluble, test DMF, NMP, or mixtures (DMSO:H2O, DMSO:buffer).
    • For preparative workup or recrystallization, a tiered screen can include: ethyl acetate, MTBE, MeOH, EtOH, acetonitrile, toluene, isopropanol, acetone, and water, selecting by polarity and hydrogen-bonding capacity.
    • For LC method development, use acetonitrile or methanol with water and volatile buffers (e.g., 0.1% formic acid or 10 mM ammonium acetate) to balance retention and ionization.
    • If the compound is ionizable, adjust pH to favor the neutral form for extraction into organic solvents (for acids, acidify aqueous phase; for bases, basify) once pKa is known.
  • Selection considerations

    • Avoid high UV cutoff solvents for UV-detection assays. For photolabile molecules, minimize exposure to light and use amber vials.
    • Ensure final assay solvent (often aqueous buffer) contains DMSO below biological tolerance thresholds (commonly ≤0.1–1% v/v). Validate solvent effects with control wells.
  • Documentation

    • Record solvent, concentration, and any pH adjustments on the vial label and ELN. Update once item-specific solubility data are obtained from CoA.
Storage and Reconstitution
  • Item-specific (from Product Data)

    • Storage conditions: Store at -20°C.
    • Shipping: Ice chest + Ice pads.
    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
    • Purity/Grade: Not specified for this item; refer to CoA/Spec Sheet.
  • Reconstitution (general guidance for small-molecule solids; not item-specific)

    • Allow vial to equilibrate to room temperature in a desiccator before opening to prevent moisture condensation.
    • Prepare a primary stock solution in anhydrous DMSO (e.g., 10–50 mM). If insoluble, trial DMF or a co-solvent system. Record exact mass, solvent, and calculated concentration corrected for salt/solvate if applicable.
    • Filter only if necessary and compatible; verify recovery if filtering low-concentration solutions.
    • Aliquot stock solutions into inert, airtight vials (preferably amber) to avoid repeated freeze–thaw cycles. Store aliquots at -20°C.
  • Stability and handling

    • Protect from light until photostability is known. Minimize exposure to ambient humidity.
    • For working solutions in aqueous buffers, prepare fresh on the day of use unless stability is confirmed by LC–MS.

For definitive instructions (including any item-specific solubility, stability, or reconstitution notes), consult the batch CoA and SDS.

Structure and Identity

Brief overview: GDC-0339 is listed as a small-molecule screening compound; however, structural identifiers are not provided in the current Product Data.

  • Item-specific (from Product Data)

    • Product name: GDC-0339 (SKU: G646647)
    • CAS: 1428569-85-0
    • InChIKey: 238976 (as provided; format appears non-standard — verify against CoA/SDS)
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Structural features

    • Not available in the Product Data. Without a SMILES/InChI or a 2D structure, functional groups, ring systems, and stereochemistry cannot be summarized for this item. Please consult the CoA or contact Technical Support for full identity data.
  • General guidance (chemistry data handling)

    • For small-molecule library members, the minimal identity set typically includes: IUPAC or accepted project code name, CAS RN, exact mass, molecular formula, SMILES, InChI, and InChIKey. When any element is missing, confirm via the batch-specific CoA and SDS prior to use in regulated workflows.
    • If establishing internal reference records, capture vendor lot, purity/grade, and any salt/solvate form once known (free base vs salt can affect solubility and assay concentration calculations).
Synthetic Utility
  • Item-specific synthetic roles

    • Not specified for this item. Without structural or functional group information, we cannot ascribe reactivity, protecting-group strategies, or derivatization pathways for GDC-0339.
  • General considerations (not item-specific)

    • If the structure contains common handles (amines, phenols, acids, halides), late-stage diversification via amide coupling, Buchwald–Hartwig, Suzuki–Miyaura, or nucleophilic substitutions may be feasible.
    • For SAR expansion, maintain a reliable analytical suite (LC–MS, 1H/13C NMR, HRMS) and track stereochemical integrity if chiral centers are present.
    • Purification strategies typically include flash chromatography (silica, reverse phase), recrystallization, or preparative HPLC. Choose solvents with attention to green chemistry where possible.
  • Intellectual property and provenance

    • When working with codename molecules (e.g., “GDC-” series), ensure that any synthetic modification or use complies with institutional IP policies and applicable licenses.

To plan synthetic work or analog preparation, obtain the full structure (SMILES/InChI) and confirm the exact salt/solvate form from the CoA.

Target Specificity
  • Item-specific target/biomolecule specificity

    • Not specified for this item; no target class, enzyme/receptor, or binding data are provided in the Product Data for GDC-0339.
  • General guidance (not item-specific)

    • If using as a putative probe, independently confirm target engagement by orthogonal methods (e.g., biochemical inhibition/activation assay, cellular readout, thermal shift/DSF, CETSA, or chemoproteomics if a handle is present).
    • Evaluate selectivity across related isoforms or family members to contextualize observed phenotypes, using standardized panels where available.
    • Report concentrations as free (unbound) where nonspecific binding to serum proteins or plastics is suspected.

Only target specificity supported by the item’s CoA/technical note should be cited in publications.

Häufig gestellte Fragen

What is the purity of this product?
This product is supplied at ≥99% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.
How should this product be stored?
Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 1428569-85-0, the molecular formula is C20H22F3N7OS, and the molecular weight is 465.50 g/mol. InChIKey NHXVGMQFCYBLTL-ZWNOBZJWSA-N.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Dürfen wir Sie über Rabattaktionen informieren?

Später erinnern

Vielen Dank! Bitte überprüfen Sie Ihren E-Mail-Posteingang, um zu bestätigen.

Hoppla! Benachrichtigungen sind deaktiviert.